Copyright: BOAI NKY Medical Technology Group Ltd., Registration No beijing ICP Prepare NO:17048418号-1
SPICM-DNA automatic cell tumor screening analysis system
SPICM-DNA automatic cell tumor screening analysis system
SPICM-DNA automatic cell tumor screening analysis system developed by the company independent, with independent intellectual property rights, the system relies on cellular DNA ploidy quantitative analysis technology, the use of today's world's fastest imaging and highest resolution area CCD Spectral imaging allows full-field scanning of the cells on the slide within 3-6 minutes and calculates the DNA content of the nucleus based on 125 relevant parameters detected in each nucleus. Automated analysis by software developed by the company and relying on the company's huge database resources to identify diseased cells from a large number of test cells and provide timely and effective cancer or precancerous lesions such as cervical cancer, lung cancer, liver cancer, prostate cancer and the like Diagnose based on. Compared with the current mainstream cell morphology detection methods, SPICM-DNA automatic cell tumor screening analysis system used in cell DNA ploidy quantitative analysis technology can greatly improve the detection sensitivity and reduce the possibility of missed diagnosis, in the full Play off the cytological examination is simple, low cost, no damage, the patient is easy to accept other advantages, while overcoming the smear poor quality, observable cells less, the detection sensitivity of the shortcomings of the pathological diagnosis of cytology into the exfoliation Brand-new areas make large-scale anti-cancer census a reality. The main features of this device are as follows: (1) The combination of qualitative and quantitative analysis can reduce the rate of misdiagnosis and early detection of precancerous lesions. Specimens of cells can be observed by microscope after being specially stained on the basis of liquid-based cytology Learn the characteristics of the cell qualitative analysis of the occurrence of lesions; the same time by automatic DNA analysis of DNA content in the nucleus and ploidy quantitative analysis and detection, accurately identify the occurrence of diseased cells. By combining qualitative and quantitative analysis, the detection sensitivity can be greatly improved, the possibility of missed diagnosis can be reduced, and precancerous lesions and the degree of lesion can be detected early before significant changes in cell morphology, leaving a large amount of treatment time for clinical treatment. ② high degree of automation of the diagnostic process to reduce the working intensity of the doctor The equipment is highly automated, the detection process without human intervention, and the test results are more objective and true, can improve the accuracy of the test at the same time, reduce the doctor's labor intensity and improve the work of doctors Efficiency and ease of promotion and use in clinical hospitals, especially primary hospitals, can effectively alleviate the contradiction between the lack of experienced cytology doctors in primary medical institutions. Haier medical R & D and production of "SPICM-DNA automatic cell tumor screening analysis system" was first registered in 2006, access to Hubei Province Food and Drug Administration issued the "People's Republic of China Medical Device Registration Card," and in 2009 Year, re-registered in 2013, registration number: Ehan food and drug administration (prospective) word 2013 No. 2400976